Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pea power: fermented legume snack shows promise for metabolic health

NCT ID NCT06743828

Disease control Sponsor: University of Eastern Finland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether eating a fermented pea-and-legume product for three weeks could improve gut health and reduce inflammation in people with metabolic syndrome. 56 adults with a large waist and at least one other risk factor (like high blood sugar or cholesterol) took part. Each person ate both the fermented and unfermented versions at different times, with a break in between. Researchers measured blood markers, gut bacteria, and digestive symptoms to see if the fermented version offered extra benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

56 people

The number who actually took part.

Started

Jan 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Waist circumference \>90 cm (women) or \>100 cm (men) OR BMI 27-35 kg/m2 * One of the following: * raised blood pressure (systolic ≥ 130 mmHg and/or diastolic 85 mmHg) * raised fasting plasma glucose (≥ 5.6 mmol/l) * raised triglycerides (≥ 1.7 mmol/l) * raised total cholesterol (≥ 5 mmol/l) * raised LDL (≥ 3 mmol/l) * reduced HDL (women \< 1.3 mmol/l, men 1.0 mmol/l) * Consumption of at least one meal where the main protein source is meat, fish, or meat alternative on most days * Willingness to follow intervention diets for the whole study Exclusion Criteria: * Diagnosed chronic diseases and conditions which could hamper the adherence to the dietary intervention protocol, e.g., type 1 or 2 diabetes, chronic liver, thyroid, kidney, or gastrointestinal diseases * Pregnancy and lactation * Gluten-free or vegan diet * Recent use of antibiotics (within 3 months) * Gastrointestinal surgery (within 6 months) * Alcohol abuse (AUDIT ≥ 15 p and measures of liver function) * regular smoking or use of snus or nicotine bags

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome

Contacts and locations

Locations

  • Institute of Public Health and Clinical Nutrition, University of Eastern Finland

    Kuopio, 70110, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.